Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 9 of 12 for:    18779236 [PUBMED-IDS]

Metformin Therapy for Overweight Adolescents With Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01881828
Recruitment Status : Completed
First Posted : June 20, 2013
Results First Posted : December 19, 2018
Last Update Posted : December 19, 2018
Sponsor:
Collaborator:
Juvenile Diabetes Research Foundation
Information provided by (Responsible Party):
Jaeb Center for Health Research

Study Type Interventional
Study Design Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition Type 1 Diabetes
Interventions Drug: Metformin (glucophage)
Other: oral placebo
Enrollment 164
Recruitment Details  
Pre-assignment Details  
Arm/Group Title Metformin Oral Placebo
Hide Arm/Group Description

Metformin 2000 mg per day

Metformin (glucophage): The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

A central pharmacy will compound a placebo to match the metformin tablets.

The placebo product will contain the following components:

  • Micosolle™, silica based excipient
  • Silicified Micro Crystalline Cellulose, National Formulary
  • Safflower Oil, United States Pharmacopeia
  • K-30 Povidone Powder
  • Magnesium Stearate, National Formulary (Vegetable source)
  • Fumed Silica, National Formulary

oral placebo

Period Title: Overall Study
Started 71 [1] 69 [2]
Completed 71 69
Not Completed 0 0
[1]
23 excluded at randomization from enrollment
[2]
23 excluded from randomization from enrollment
Arm/Group Title Metformin Oral Placebo Total
Hide Arm/Group Description

Metformin 2000 mg per day

Metformin (glucophage): The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

A central pharmacy will compound a placebo to match the metformin tablets.

The placebo product will contain the following components:

  • Micosolle™, silica based excipient
  • Silicified Micro Crystalline Cellulose, National Formulary
  • Safflower Oil, United States Pharmacopeia
  • K-30 Povidone Powder
  • Magnesium Stearate, National Formulary (Vegetable source)
  • Fumed Silica, National Formulary

oral placebo

Total of all reporting groups
Overall Number of Baseline Participants 71 69 140
Hide Baseline Analysis Population Description
[Not Specified]
Age, Continuous  
Mean (Standard Deviation)
Unit of measure:  Years
Number Analyzed 71 participants 69 participants 140 participants
15.4  (1.7) 15.1  (1.8) 15.3  (1.7)
Age, Customized  
Measure Type: Number
Unit of measure:  Years
Number Analyzed 71 participants 69 participants 140 participants
12-15 years 43 47 90
16-19 years 28 22 50
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 71 participants 69 participants 140 participants
Female
44
  62.0%
48
  69.6%
92
  65.7%
Male
27
  38.0%
21
  30.4%
48
  34.3%
Race/Ethnicity, Customized  
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 71 participants 69 participants 140 participants
White 51 52 103
Black 4 5 9
Hispanic or Latino 13 11 24
Asian 2 0 2
More than one race 1 1 2
Duration of Diabetes  
Mean (Standard Deviation)
Unit of measure:  Years
Number Analyzed 71 participants 69 participants 140 participants
7.5  (3.6) 6.4  (3.0) 7.0  (3.6)
Duration of Diabetes (group)  
Measure Type: Number
Unit of measure:  Years
Number Analyzed 71 participants 69 participants 140 participants
1-2 Years 5 9 14
3-5 Years 23 25 48
6-8 Years 19 22 41
≥ 9 years 24 13 37
Body Mass Index (BMI) Z Score   [1] 
Mean (Standard Deviation)
Unit of measure:  Z score
Number Analyzed 71 participants 69 participants 140 participants
1.6  (0.4) 1.7  (0.3) 1.6  (0.3)
[1]
Measure Description: Body mass index z-scores are measures of relative weight adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate BMI values lower than the mean and positive numbers indicate BMI values higher than the mean.
Body Mass Index (BMI) Percentile Group  
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 71 participants 69 participants 140 participants
Overweight: 85th-<95th% 36 26 62
Obese: ≥ 95th % 33 41 74
Tanner Staging (Pubic Hair)   [1] 
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 71 participants 69 participants 140 participants
Stage 1 1 1 2
Stage 2 1 3 4
Stage 3 5 7 12
Stage 4 16 9 25
Stage 5 48 49 97
[1]
Measure Description: For all three sites of development, Tanner Stage 1 corresponds to the pre-pubertal form with progression to Tanner Stage 5, the final adult form.
Tanner Staging (Breasts/Genitals)   [1] 
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 71 participants 69 participants 140 participants
Stage 1 1 1 2
Stage 2 0 2 2
Stage 3 5 6 11
Stage 4 12 9 21
Stage 5 53 51 104
[1]
Measure Description: For all three sites of development, Tanner Stage 1 corresponds to the pre-pubertal form with progression to Tanner Stage 5, the final adult form.
Highest Parent Educaiton Level  
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 71 participants 69 participants 140 participants
High school diploma, GED, or less 22 20 42
Associate 10 12 22
Bachelor 18 15 33
Master 12 13 25
Professional 5 7 12
Unknown / Do not want to answer 4 2 6
Income Category  
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 71 participants 69 participants 140 participants
Less than $35,000 5 7 12
$35,000 to less than $50,000 3 7 10
$50,000 to less than $75,000 10 13 23
$75,000 to less than $100,000 14 12 26
$100,000 to less than $200,000 5 6 11
Unknown / Do not want to answer 23 18 41
Insurance  
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 71 participants 69 participants 140 participants
Private Insurance 53 48 101
Other Insurance 14 15 29
None 0 2 2
Unknown / Do not want to answer 4 4 8
Severe Hypoglycemia Events Since T1D Diagnosis  
Measure Type: Number
Unit of measure:  Episodes
Number Analyzed 71 participants 69 participants 140 participants
None 52 52 104
1-2 episodes 14 10 24
3-4 episodes 3 2 5
≥ 5 episodes 2 5 7
Diabetic Ketoacidosis Events Since T1D Diagnosis  
Measure Type: Number
Unit of measure:  Episodes
Number Analyzed 71 participants 69 participants 140 participants
None 53 48 101
1-2 episodes 15 13 28
3-4 episodes 2 6 8
≥ 5 episodes 1 2 3
HbA1c Lab  
Mean (Standard Deviation)
Unit of measure:  Percentage
Number Analyzed 71 participants 69 participants 140 participants
8.8  (0.8) 8.8  (0.7) 8.8  (0.7)
HbA1c Group  
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 71 participants 69 participants 140 participants
< 8.5% 25 24 49
8.5%-9.4% 32 26 58
≥ 9.5% 14 19 33
Mean Sensor Glucose  
Mean (Standard Deviation)
Unit of measure:  mg/dL
Number Analyzed 71 participants 69 participants 140 participants
206  (35) 208  (34) 207  (34.6)
Insulin Pump Use  
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 71 participants 69 participants 140 participants
50 49 99
Continuous Glucose Monitor Use  
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 71 participants 69 participants 140 participants
2 2 4
Self-Monitoring of Blood Glucose per day  
Mean (Standard Deviation)
Unit of measure:  Number of checks per day
Number Analyzed 71 participants 69 participants 140 participants
4.5  (1.2) 4.6  (1.6) 4.5  (1.4)
Self-Monitoring of Blood Glucose group  
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 71 participants 69 participants 140 participants
3 13 14 27
4-5 44 43 87
≥ 6 14 12 26
Total Daily Insulin  
Mean (Standard Deviation)
Unit of measure:  Unit/kg/day
Number Analyzed 71 participants 69 participants 140 participants
1.1  (0.2) 1.1  (0.2) 1.1  (0.2)
Total Daily Insulin Group  
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 71 participants 69 participants 140 participants
<1.0 33 26 59
1.0-1.4 33 39 72
≥ 1.5 5 4 9
Total Basal/Long Acting Insulin  
Mean (Standard Deviation)
Unit of measure:  Unit/kg/day
Number Analyzed 71 participants 69 participants 140 participants
0.5  (0.1) 0.5  (0.1) 0.5  (0.1)
Body Mass Index (BMI) Percentile  
Mean (Standard Deviation)
Unit of measure:  Percentile
Number Analyzed 71 participants 69 participants 140 participants
93.7  (4.1) 94.3  (3.8) 94  (3.9)
1.Primary Outcome
Title Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c.
Hide Description Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months
Time Frame 0-26 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Metformin Oral Placebo
Hide Arm/Group Description:

Metformin 2000 mg per day

Metformin (glucophage): The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

A central pharmacy will compound a placebo to match the metformin tablets.

The placebo product will contain the following components:

  • Micosolle™, silica based excipient
  • Silicified Micro Crystalline Cellulose, National Formulary
  • Safflower Oil, United States Pharmacopeia
  • K-30 Povidone Powder
  • Magnesium Stearate, National Formulary (Vegetable source)
  • Fumed Silica, National Formulary

oral placebo

Overall Number of Participants Analyzed 71 69
Mean (95% Confidence Interval)
Unit of Measure: percentage
HbA1c
9.0
(8.8 to 9.2)
8.9
(8.7 to 9.2)
Change from Baseline to 26 Weeks
0.2
(0.0 to 0.4)
0.2
(-0.1 to 0.4)
2.Primary Outcome
Title Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c.
Hide Description Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months
Time Frame 0-26 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Metformin Oral Placebo
Hide Arm/Group Description:

Metformin 2000 mg per day

Metformin (glucophage): The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

A central pharmacy will compound a placebo to match the metformin tablets.

The placebo product will contain the following components:

  • Micosolle™, silica based excipient
  • Silicified Micro Crystalline Cellulose, National Formulary
  • Safflower Oil, United States Pharmacopeia
  • K-30 Povidone Powder
  • Magnesium Stearate, National Formulary (Vegetable source)
  • Fumed Silica, National Formulary

oral placebo

Overall Number of Participants Analyzed 71 69
Measure Type: Number
Unit of Measure: percentage of participants
HbA1c Decrease ≥0.5% 19 18
HbA1c Increase ≥0.5% 44 35
HbA1c <7.5% 3 4
3.Secondary Outcome
Title Change in Total Daily Dose of Insulin (TDI) Per kg
Hide Description [Not Specified]
Time Frame 0-26 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Metformin Oral Placebo
Hide Arm/Group Description:

Metformin 2000 mg per day

Metformin (glucophage): The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

A central pharmacy will compound a placebo to match the metformin tablets.

The placebo product will contain the following components:

  • Micosolle™, silica based excipient
  • Silicified Micro Crystalline Cellulose, National Formulary
  • Safflower Oil, United States Pharmacopeia
  • K-30 Povidone Powder
  • Magnesium Stearate, National Formulary (Vegetable source)
  • Fumed Silica, National Formulary

oral placebo

Overall Number of Participants Analyzed 71 69
Mean (95% Confidence Interval)
Unit of Measure: insulin per kg
-0.1
(-0.1 to -0.1)
-0.0
(-0.1 to -0.0)
4.Secondary Outcome
Title Change in Body Mass Index (BMI)
Hide Description [Not Specified]
Time Frame 0-26 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Metformin Oral Placebo
Hide Arm/Group Description:

Metformin 2000 mg per day

Metformin (glucophage): The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

A central pharmacy will compound a placebo to match the metformin tablets.

The placebo product will contain the following components:

  • Micosolle™, silica based excipient
  • Silicified Micro Crystalline Cellulose, National Formulary
  • Safflower Oil, United States Pharmacopeia
  • K-30 Povidone Powder
  • Magnesium Stearate, National Formulary (Vegetable source)
  • Fumed Silica, National Formulary

oral placebo

Overall Number of Participants Analyzed 71 69
Mean (95% Confidence Interval)
Unit of Measure: percentile
-1
(-2 to 0)
1
(-0.0 to 1)
5.Secondary Outcome
Title Change in Waist Circumference
Hide Description [Not Specified]
Time Frame 0-26 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Metformin Oral Placebo
Hide Arm/Group Description:

Metformin 2000 mg per day

Metformin (glucophage): The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

A central pharmacy will compound a placebo to match the metformin tablets.

The placebo product will contain the following components:

  • Micosolle™, silica based excipient
  • Silicified Micro Crystalline Cellulose, National Formulary
  • Safflower Oil, United States Pharmacopeia
  • K-30 Povidone Powder
  • Magnesium Stearate, National Formulary (Vegetable source)
  • Fumed Silica, National Formulary

oral placebo

Overall Number of Participants Analyzed 71 69
Mean (95% Confidence Interval)
Unit of Measure: centimeters
-0
(-2 to 1)
1
(-1 to 3)
6.Secondary Outcome
Title Change in Body Composition
Hide Description Change in percent body fat
Time Frame 0-26 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Metformin Oral Placebo
Hide Arm/Group Description:

Metformin 2000 mg per day

Metformin (glucophage): The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

A central pharmacy will compound a placebo to match the metformin tablets.

The placebo product will contain the following components:

  • Micosolle™, silica based excipient
  • Silicified Micro Crystalline Cellulose, National Formulary
  • Safflower Oil, United States Pharmacopeia
  • K-30 Povidone Powder
  • Magnesium Stearate, National Formulary (Vegetable source)
  • Fumed Silica, National Formulary

oral placebo

Overall Number of Participants Analyzed 71 69
Mean (95% Confidence Interval)
Unit of Measure: percentage of change
-0
(-1 to 1)
1
(0 to 1)
7.Secondary Outcome
Title Change in Serum Lipids
Hide Description [Not Specified]
Time Frame 0-26 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Metformin Oral Placebo
Hide Arm/Group Description:

Metformin 2000 mg per day

Metformin (glucophage): The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

A central pharmacy will compound a placebo to match the metformin tablets.

The placebo product will contain the following components:

  • Micosolle™, silica based excipient
  • Silicified Micro Crystalline Cellulose, National Formulary
  • Safflower Oil, United States Pharmacopeia
  • K-30 Povidone Powder
  • Magnesium Stearate, National Formulary (Vegetable source)
  • Fumed Silica, National Formulary

oral placebo

Overall Number of Participants Analyzed 71 69
Mean (95% Confidence Interval)
Unit of Measure: mg/dL
Change in LDL
-6
(-11 to -0)
2
(-3 to 7)
Change in VLDL
-0
(-3 to 2)
1
(-1 to 3)
Change in HDL
-0
(-2 to 2)
-1
(-2 to 1)
Change in Triglycerides
4
(-5 to 13)
6
(-5 to 17)
Change in Total Cholesterol
-5
(-11 to 1)
3
(-3 to 8)
8.Secondary Outcome
Title Change in Blood Pressure
Hide Description [Not Specified]
Time Frame 0-26 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Metformin Oral Placebo
Hide Arm/Group Description:

Metformin 2000 mg per day

Metformin (glucophage): The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

A central pharmacy will compound a placebo to match the metformin tablets.

The placebo product will contain the following components:

  • Micosolle™, silica based excipient
  • Silicified Micro Crystalline Cellulose, National Formulary
  • Safflower Oil, United States Pharmacopeia
  • K-30 Povidone Powder
  • Magnesium Stearate, National Formulary (Vegetable source)
  • Fumed Silica, National Formulary

oral placebo

Overall Number of Participants Analyzed 71 69
Mean (95% Confidence Interval)
Unit of Measure: mm Hg
Change in Systolic
0
(-0 to 0)
-0
(-0 to 0)
Change in Diastolic
0
(-0 to 0)
0
(-0 to 0)
9.Other Pre-specified Outcome
Title Change in Liver Enzymes and Serum Creatinine
Hide Description [Not Specified]
Time Frame 0-26 weeks
Outcome Measure Data Not Reported
10.Other Pre-specified Outcome
Title Frequency of Severe Hypoglycemia
Hide Description [Not Specified]
Time Frame 26 weeks
Outcome Measure Data Not Reported
11.Other Pre-specified Outcome
Title Frequency of Diabetic Ketoacidosis
Hide Description [Not Specified]
Time Frame 26 weeks
Outcome Measure Data Not Reported
12.Other Pre-specified Outcome
Title Frequency of Gastrointestinal Side-effects Including Stomach Discomfort, Diarrhea, Nausea/Vomiting, Indigestion, Flatulence.
Hide Description [Not Specified]
Time Frame 26 weeks
Outcome Measure Data Not Reported
13.Other Pre-specified Outcome
Title Frequency of Lactic Acidosis
Hide Description [Not Specified]
Time Frame 26 weeks
Outcome Measure Data Not Reported
14.Other Pre-specified Outcome
Title Change in Adipocytokines
Hide Description [Not Specified]
Time Frame 0-26 weeks
Outcome Measure Data Not Reported
15.Other Pre-specified Outcome
Title Change in Androgen Levels in Females
Hide Description [Not Specified]
Time Frame 0-26 weeks
Outcome Measure Data Not Reported
16.Other Pre-specified Outcome
Title Change in C-peptide
Hide Description Measured with mixed meal tolerance test among participants with evidence of residual C-peptide on a non-fasting C-peptide at screening
Time Frame 0-26-weeks
Outcome Measure Data Not Reported
17.Other Pre-specified Outcome
Title Change in Vascular Dysfunction
Hide Description [Not Specified]
Time Frame 0-26 weeks
Outcome Measure Data Not Reported
Time Frame [Not Specified]
Adverse Event Reporting Description [Not Specified]
 
Arm/Group Title Metformin Oral Placebo
Hide Arm/Group Description

Metformin 2000 mg per day

Metformin (glucophage): The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

A central pharmacy will compound a placebo to match the metformin tablets.

The placebo product will contain the following components:

  • Micosolle™, silica based excipient
  • Silicified Micro Crystalline Cellulose, National Formulary
  • Safflower Oil, United States Pharmacopeia
  • K-30 Povidone Powder
  • Magnesium Stearate, National Formulary (Vegetable source)
  • Fumed Silica, National Formulary

oral placebo

All-Cause Mortality
Metformin Oral Placebo
Affected / at Risk (%) Affected / at Risk (%)
Total   --/--      --/--    
Show Serious Adverse Events Hide Serious Adverse Events
Metformin Oral Placebo
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total   3/71 (4.23%)      3/69 (4.35%)    
Endocrine disorders     
Diabetic Ketoacidosis  3/71 (4.23%)  3 3/69 (4.35%)  3
Show Other (Not Including Serious) Adverse Events Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 0%
Metformin Oral Placebo
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total   0/71 (0.00%)      0/69 (0.00%)    
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title: Kellee Miller
Organization: Jaeb Center for Health Research
Phone: 15310 Amberly Drive
Publications:
Responsible Party: Jaeb Center for Health Research
ClinicalTrials.gov Identifier: NCT01881828     History of Changes
Other Study ID Numbers: T1DX-17-2013-506
17-2013-506 ( Other Grant/Funding Number: JDRF )
First Submitted: June 13, 2013
First Posted: June 20, 2013
Results First Submitted: March 10, 2017
Results First Posted: December 19, 2018
Last Update Posted: December 19, 2018